Every round on record, with the sources behind each and the investors on them.
Treeline develops innovative medicines targeting serious diseases, primarily in oncology, immunology, and neurology.
treeline.bioBiotech
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source names investors to date but does not identify them as participants in this extension, nor does it name a lead investor. The $1.1 billion figure is total funding, not this round’s amount.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A ext. series A extension [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M $1.1B to date | 2025-09-03 | not stated | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The source names investors to date but does not identify them as participants in this extension, nor does it name a lead investor. The $1.1 billion figure is total funding, not this round’s amount. | ||||
None named.